Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism - PubMed
3 hours ago
- #bone remodeling
- #hypoparathyroidism
- #PTH(1-34)
- PTH(1-34) therapy, used off-label, effectively controls serum calcium in chronic hypoparathyroidism inadequately managed by standard therapy.
- Long-term PTH(1-34) therapy strongly stimulates bone remodeling, often raising bone turnover markers above normal levels.
- A study of 41 patients treated with PTH(1-34) for over 2 years found pathological bone uptake in 61% despite adequate serum calcium control.
- Patients with pathological bone uptake had higher weight-adjusted PTH(1-34) doses, elevated bone remodeling markers, lower serum magnesium, and increased urinary calcium excretion.
- A score combining serum C-telopeptides of collagen I, osteocalcin, and magnesium correctly classified 97% of patients regarding bone overstimulation risk.
- Careful monitoring is essential during long-term PTH(1-34) therapy, especially in patients with elevated bone turnover markers and hypomagnesemia.